These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Risk factors for clinical manifestations in carriers of Factor V Leiden and prothrombin gene mutations. DeSancho MT; Berlus N; Christos PJ; Rand J Blood Coagul Fibrinolysis; 2010 Jan; 21(1):11-5. PubMed ID: 19474699 [TBL] [Abstract][Full Text] [Related]
23. [Clinical findings in individuals with the factor V Leiden mutation]. Matýsková M; Vorlová Z; Hrachovinová I; Buliková A; Zavrelová J; Slechtová M Vnitr Lek; 1997 May; 43(5):298-301. PubMed ID: 9601852 [TBL] [Abstract][Full Text] [Related]
24. The Leiden mutation of coagulation factor V in Hungarian SLE patients. Regéczy N; Lakos G; Balogh I; Ajzner E; Kiss E; Szegedi G Clin Appl Thromb Hemost; 2000 Jan; 6(1):41-5. PubMed ID: 10726048 [TBL] [Abstract][Full Text] [Related]
26. Effect of hemostatic risk factors on the individual probability of thrombosis during pregnancy and the puerperium. Gerhardt A; Scharf RE; Zotz RB Thromb Haemost; 2003 Jul; 90(1):77-85. PubMed ID: 12876629 [TBL] [Abstract][Full Text] [Related]
27. Factor V gene A4070G mutation and the risk of cerebral veno-sinus thrombosis occurring during puerperium. Dindagur N; Kruthika-Vinod TP; Christopher R Thromb Res; 2007; 119(4):497-500. PubMed ID: 16781765 [TBL] [Abstract][Full Text] [Related]
28. Thrombotic tendency in 75 symptomatic, unrelated patients with APC resistance. Melichart M; Kyrle PA; Eichinger S; Rintelen C; Mannhalter C; Pabinger I Wien Klin Wochenschr; 1996; 108(19):607-10. PubMed ID: 8921576 [TBL] [Abstract][Full Text] [Related]
29. Thrombosis in otherwise well children with the factor V Leiden mutation. Sifontes MT; Nuss R; Jacobson LJ; Griffin JH; Manco-Johnson MJ J Pediatr; 1996 Mar; 128(3):324-8. PubMed ID: 8774498 [TBL] [Abstract][Full Text] [Related]
30. First-trimester repeated abortion is not associated with activated protein C resistance. Balasch J; Reverter JC; Fábregues F; Tàssies D; Rafel M; Creus M; Vanrell JA Hum Reprod; 1997 May; 12(5):1094-7. PubMed ID: 9194672 [TBL] [Abstract][Full Text] [Related]
31. Discrimination between normal wildtype and carriers of coagulation factor V Leiden mutation by the activated protein C resistance test in the presence of factor V deficient plasma. Reuner KH; Litfin F; Patscheke H Eur J Clin Chem Clin Biochem; 1997 Jan; 35(1):41-5. PubMed ID: 9156566 [TBL] [Abstract][Full Text] [Related]
32. Risk factor profiles in patients with different clinical manifestations of venous thromboembolism: a focus on the factor V Leiden mutation. Manten B; Westendorp RG; Koster T; Reitsma PH; Rosendaal FR Thromb Haemost; 1996 Oct; 76(4):510-3. PubMed ID: 8902987 [TBL] [Abstract][Full Text] [Related]
33. Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. Deschiens MA; Conard J; Horellou MH; Ameri A; Preter M; Chedru F; Samama MM; Bousser MG Stroke; 1996 Oct; 27(10):1724-30. PubMed ID: 8841318 [TBL] [Abstract][Full Text] [Related]
34. Is the prevalence of the factor V Leiden mutation in patients with pulmonary embolism and deep vein thrombosis really different? Turkstra F; Karemaker R; Kuijer PM; Prins MH; Büller HR Thromb Haemost; 1999 Mar; 81(3):345-8. PubMed ID: 10102457 [TBL] [Abstract][Full Text] [Related]
35. Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden. Weitz IC; Israel VK; Liebman HA Cancer; 1997 May; 79(10):2024-7. PubMed ID: 9149031 [TBL] [Abstract][Full Text] [Related]
36. Pulmonary embolism and premature labor in a patient with both factor V Leiden mutation and methylenetetrahydrofolate reductase gene C677T mutation. Peng F; Triplett D; Barna L; Morrical D Thromb Res; 1996 Aug; 83(3):243-51. PubMed ID: 8840466 [TBL] [Abstract][Full Text] [Related]
37. Activated-protein-C resistance in cancer patients. Green D; Maliekel K; Sushko E; Akhtar R; Soff GA Haemostasis; 1997; 27(3):112-8. PubMed ID: 9306127 [TBL] [Abstract][Full Text] [Related]
38. Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives. Aznar J; Vayá A; Estellés A; Mira Y; Seguí R; Villa P; Ferrando F; Falcó C; Corella D; España F Haematologica; 2000 Dec; 85(12):1271-6. PubMed ID: 11114134 [TBL] [Abstract][Full Text] [Related]
39. The role of natural anticoagulant deficiencies and factor V Leiden in the development of idiopathic portal vein thrombosis. Egesel T; Büyükasik Y; Dündar SV; Gürgey A; Kirazli S; Bayraktar Y J Clin Gastroenterol; 2000 Jan; 30(1):66-71. PubMed ID: 10636214 [TBL] [Abstract][Full Text] [Related]
40. "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds. Simioni P; Scudeller A; Radossi P; Gavasso S; Girolami B; Tormene D; Girolami A Thromb Haemost; 1996 Mar; 75(3):422-6. PubMed ID: 8701401 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]